• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Incannex Healthcare Appoints Alison Wimms, Ph.D. to Newly Formed IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board

    2/4/25 9:15:00 AM ET
    $IXHL
    $RMD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $IXHL alert in real time by email

    NEW YORK and MELBOURNE, Australia, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing combination medicines today announced the appointment of Alison Wimms, Ph.D. as an advisor to its newly formed IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board where she will represent ResMed.

    Dr. Wimms brings two decades of sleep medicine industry and research expertise to her advisory role at Incannex. Dr. Wimms holds a Doctor of Philosophy (Ph.D.) in Medicine, and Master of Medicine (Sleep Medicine) and Bachelor of Science degrees from the University of Sydney.

    "Incannex's newly formed clinical advisory board and the appointment of Dr. Wimms underscore our continued dedication to innovation in the field of OSA and transforming patient treatment outcomes," said Joel Latham, Incannex's President and Chief Executive Officer. "We are thrilled to welcome Dr. Wimm's expertise to our IHL-42X clinical advisory board. This marks an exciting step in fostering collaboration as we advance our global Phase 2/3 ‘RePOSA' clinical study in OSA."

    "I am excited to join Incannex's OSA Clinical Advisory Board. I look forward to advising on IHL-42X late-stage clinical development," said Dr. Alison Wimms.

    About IHL-42X

    IHL-42X, an oral fixed-dose combination of acetazolamide and dronabinol, is currently in Phase 2/3 clinical studies for the treatment of obstructive sleep apnea (OSA). Designed to act synergistically, IHL-42X targets two different physiological pathways associated with the intermittent hypoxia (IH) and hypercapnia that characterize OSA. In a prior Australian Phase 2 clinical trial, IHL-42X was shown to reduce the Apnea-Hypopnea Index (AHI) in all dosage strengths, with the lowest dose reducing AHI by an average of 51 percent relative to baseline. RePOSA, a global Phase 2/3 clinical trial is underway, evaluating IHL-42X in individuals with OSA who are either non-compliant, intolerant, or naïve to positive airway pressure devices, including CPAP, with the Phase 2 portion conducted in the United States. The expanded Phase 3 portion will also include sites in the United Kingdom and European Union. A top-line readout from the U.S. Phase 2 portion is anticipated in the first half of 2025.

    About ResMed

    At ResMed (NYSE:RMD, ASX: RMD)) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries. To learn more, visit ResMed.com and follow @ResMed.

    About Incannex Healthcare Inc. 

    Incannex is leading the way in developing combination medicines that target the underlying biological pathways associated with chronic conditions, including obstructive sleep apnea, rheumatoid arthritis and generalized anxiety disorder. The company is advancing novel oral fix-dosed treatments and therapeutic regimens based on evidence-based innovation. Incannex's lead Phase 2/3 and Phase 2 clinical programs include IHL-42X, an oral fixed-dose combination of dronabinol and acetazolamide, designed to act synergistically in the treatment of OSA for the treatment of obstructive sleep apnea; IHL-675A, an oral fixed-dose combination of cannabidiol and hydroxychloroquine sulfate, acting synergistically to alleviate inflammation, and PSX-001, an oral synthetic psilocybin treatment in combination with psychotherapy, for the treatment of generalized anxiety disorder. Incannex's programs target disorders that have limited, inadequate, or no approved pharmaceutical treatment options.

    Forward Looking Statements 

    This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Examples of forward-looking statements in this press release include statements about, among other things: Incannex's business strategy, future operations; Incannex's ability to execute on its objectives, prospects, or plans, the skills and experience of the newly appointed officer of Incannex and expectations with respect to her future contributions to the Company and statements, evaluations and judgments regarding Incannex's research and development efforts, including any implications that the results of earlier clinical trials will be representative or consistent with later clinical trials or final results; the expected timing of enrollment for these trials and the availability of data or results of these trials, and the potential benefits, safety or of Incannex's drug candidates. Forward-looking statements are statements other than historical facts and relate to future events or circumstances or Incannex's future performance, and they are based on management's current assumptions, expectations, and beliefs concerning future developments and their potential effect on Incannex's business. These forward-looking statements are subject to a number of risks and uncertainties, which may cause the forward-looking events and circumstances described in this press release to not occur, and actual results to differ materially and adversely from those described in or implied by the forward-looking statements. These risks and uncertainties include, among others: the continued availability of financing; Incannex's ability to raise capital to fund continuing operations and to complete capital raising transactions; the impact of any infringement actions or other litigation brought against Incannex; the success of Incannex's development efforts, including Incannex's ability to progress its drug candidates through clinical trials on the timelines expected; competition from other providers and products; that the market for its drug candidates may not grow at the rates anticipated or at all; Incannex's compliance with the various evolving and complex laws and regulations applicable to its business and its industry; and Incannex's ability to protect its proprietary technology and intellectual property; and other factors relating to Incannex's industry, its operations and results of operations. The forward-looking statements made in this press release speak only as of the date of this press release, and Incannex assumes no obligation to update publicly any such forward-looking statements to reflect actual results or to changes in expectations, except as otherwise required by law. Incannex's reports filed with the U.S. Securities and Exchange Commission (SEC) including its annual report on Form 10-K for the fiscal year ended June 30, 2024, filed with the SEC on September 30, 2024, and the other reports it files from time to time, including subsequently filed annual, quarterly and current reports, are made available on Incannex's website upon their filing with the SEC. These reports contain more information about Incannex, its business and the risks affecting its business, as well as its results of operations for the periods covered by the financial results included in this press release.

    Contact Information

    Jennifer Drew-Bear

    Edison Group for Incannex

    [email protected]



    Primary Logo

    Get the next $IXHL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IXHL
    $RMD

    CompanyDatePrice TargetRatingAnalyst
    ResMed Inc.
    $RMD
    3/19/2025$280.00Overweight
    Morgan Stanley
    ResMed Inc.
    $RMD
    3/19/2025Overweight
    Morgan Stanley
    ResMed Inc.
    $RMD
    1/16/2025Buy
    Goldman
    ResMed Inc.
    $RMD
    1/10/2025$252.00Neutral
    Piper Sandler
    ResMed Inc.
    $RMD
    12/13/2024$250.00Hold
    Stifel
    ResMed Inc.
    $RMD
    9/24/2024$280.00Outperform
    Robert W. Baird
    ResMed Inc.
    $RMD
    9/18/2024$180.00Peer Perform → Underperform
    Wolfe Research
    ResMed Inc.
    $RMD
    9/4/2024Buy → Hold
    Needham
    More analyst ratings

    $IXHL
    $RMD
    Financials

    Live finance-specific insights

    See more
    • Resmed Acquires VirtuOx

      SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced it has acquired VirtuOx, a leading independent diagnostic testing facility (IDTF) for sleep, respiratory, and cardiac conditions. The acquisition reflects Resmed's commitment to improving the way care is delivered—by making it more accessible, more coordinated, and more patient friendly. With VirtuOx's at-home diagnostic services, Resmed will be better positioned to support patients earlier in their journey and help healthcare providers and homecare companies deliver care in a simpler, more connected wa

      5/1/25 9:00:00 AM ET
      $RMD
      Medical/Dental Instruments
      Health Care
    • Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 2025

      Year-over-year revenue grows 8%, operating profit up 14%, non-GAAP operating profit up 13%Operating cash flow of $579 million Note: A webcast of Resmed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Resmed Inc. (NYSE:RMD, ASX: RMD)) today announced results for its quarter ended March 31, 2025. Third Quarter 2025 HighlightsAll comparisons are to the prior year period Revenue increased by 8% to $1.3 billion; up 9% on a constant currency basis Gross margin improved 140 bps to 59.3%; non-GAAP gross margin improved 140 bps to 59.9%Income from operations increased 14%; non-GAAP income from operations up 13

      4/23/25 4:05:00 PM ET
      $RMD
      Medical/Dental Instruments
      Health Care
    • Resmed to Report Third Quarter Fiscal 2025 Earnings on April 23, 2025

      SAN DIEGO, April 02, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)) today announced it plans to release financial and operational results for the third quarter of fiscal year 2025 on Wednesday, April 23, 2025, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details:  •Location:https://investor.resmed.com •Date:Wednesday, April 23, 2025 •Time:1:30 p.m. PDT / 4:30 p.m. EDT •International:London, Wednesday, April 23, 2025, 9:30 p.m. BST   Sydney, Thursday, April 24, 2025, 6:30 a.m. AEST Please note,

      4/2/25 4:05:00 PM ET
      $RMD
      Medical/Dental Instruments
      Health Care

    $IXHL
    $RMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Resmed Acquires VirtuOx

      SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced it has acquired VirtuOx, a leading independent diagnostic testing facility (IDTF) for sleep, respiratory, and cardiac conditions. The acquisition reflects Resmed's commitment to improving the way care is delivered—by making it more accessible, more coordinated, and more patient friendly. With VirtuOx's at-home diagnostic services, Resmed will be better positioned to support patients earlier in their journey and help healthcare providers and homecare companies deliver care in a simpler, more connected wa

      5/1/25 9:00:00 AM ET
      $RMD
      Medical/Dental Instruments
      Health Care
    • Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 2025

      Year-over-year revenue grows 8%, operating profit up 14%, non-GAAP operating profit up 13%Operating cash flow of $579 million Note: A webcast of Resmed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Resmed Inc. (NYSE:RMD, ASX: RMD)) today announced results for its quarter ended March 31, 2025. Third Quarter 2025 HighlightsAll comparisons are to the prior year period Revenue increased by 8% to $1.3 billion; up 9% on a constant currency basis Gross margin improved 140 bps to 59.3%; non-GAAP gross margin improved 140 bps to 59.9%Income from operations increased 14%; non-GAAP income from operations up 13

      4/23/25 4:05:00 PM ET
      $RMD
      Medical/Dental Instruments
      Health Care
    • Resmed Names Salli Schwartz as Chief Investor Relations Officer

      SAN DIEGO, April 21, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD), ASX: RMD), the global leader in health technology focused on sleep, breathing, and care delivered in the home, today announced the appointment of Salli Schwartz as Chief Investor Relations Officer, effective April 21, 2025. In this role, Schwartz will lead Resmed's global investor relations function and report to Mick Farrell, Chairman of the Board and CEO. Schwartz is a seasoned executive with more than two decades of experience in a range of finance roles at health tech and financial services organizations. She joins Resmed from Illumina, Inc., where she served as the Head of Investor Relations. In that role, she

      4/21/25 5:00:00 PM ET
      $RMD
      Medical/Dental Instruments
      Health Care

    $IXHL
    $RMD
    Leadership Updates

    Live Leadership Updates

    See more
    • Resmed Names Salli Schwartz as Chief Investor Relations Officer

      SAN DIEGO, April 21, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD), ASX: RMD), the global leader in health technology focused on sleep, breathing, and care delivered in the home, today announced the appointment of Salli Schwartz as Chief Investor Relations Officer, effective April 21, 2025. In this role, Schwartz will lead Resmed's global investor relations function and report to Mick Farrell, Chairman of the Board and CEO. Schwartz is a seasoned executive with more than two decades of experience in a range of finance roles at health tech and financial services organizations. She joins Resmed from Illumina, Inc., where she served as the Head of Investor Relations. In that role, she

      4/21/25 5:00:00 PM ET
      $RMD
      Medical/Dental Instruments
      Health Care
    • Incannex Healthcare Inc. Reports Fiscal Second Quarter 2025 Financial Results and Business Updates

      Positive IHL-42X PK findings for the treatment of Obstructive Sleep Apnea (OSA) support future 505(b)(2) New Drug Application (NDA) submissionNew OSA Clinical Advisory Board Announced; Appoints Dr. Alison Wimms, Representing ResMed NEW YORK and MELBOURNE, Australia, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing oral combination medicines, today reported fiscal second quarter financial results and provided business highlights for the quarter ended December 31, 2024. "Patients with obstructive sleep apnea need new and convenient therapeutic options to manage this serious, chroni

      2/14/25 7:30:00 AM ET
      $IXHL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jan De Witte joins GHO Capital as Operating Partner

      Jan De Witte joins GHO Capital as Operating Partner Former CEO of Integra LifeSciences with significant strategic and operational experience to support GHO Capital's portfolio London, UK – 11 February 2025: Global Healthcare Opportunities, or GHO Capital Partners LLP ("GHO"), the European specialist investor in global healthcare, is pleased to announce the appointment of Jan De Witte as Operating Partner. Jan is an accomplished senior executive with extensive experience leading international growth and transformation for global technology and life sciences companies. Prior to joining GHO, he was Chief Executive Officer and member of the Board of Directors at Integra LifeSciences (("Integr

      2/11/25 4:30:00 AM ET
      $IART
      $RMD
      Medical/Dental Instruments
      Health Care

    $IXHL
    $RMD
    SEC Filings

    See more
    • SEC Form 144 filed by ResMed Inc.

      144 - RESMED INC (0000943819) (Subject)

      5/7/25 8:12:48 PM ET
      $RMD
      Medical/Dental Instruments
      Health Care
    • SEC Form EFFECT filed by Incannex Healthcare Inc.

      EFFECT - Incannex Healthcare Inc. (0001873875) (Filer)

      4/29/25 12:15:05 AM ET
      $IXHL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B3 filed by Incannex Healthcare Inc.

      424B3 - Incannex Healthcare Inc. (0001873875) (Filer)

      4/28/25 4:06:50 PM ET
      $IXHL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IXHL
    $RMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $IXHL
    $RMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Morgan Stanley initiated coverage on ResMed with a new price target

      Morgan Stanley initiated coverage of ResMed with a rating of Overweight and set a new price target of $280.00

      3/19/25 10:13:23 AM ET
      $RMD
      Medical/Dental Instruments
      Health Care
    • Morgan Stanley initiated coverage on ResMed

      Morgan Stanley initiated coverage of ResMed with a rating of Overweight

      3/19/25 8:18:03 AM ET
      $RMD
      Medical/Dental Instruments
      Health Care
    • Goldman initiated coverage on ResMed

      Goldman initiated coverage of ResMed with a rating of Buy

      1/16/25 7:53:14 AM ET
      $RMD
      Medical/Dental Instruments
      Health Care
    • Director Farrell Peter C sold $484,500 worth of ResMed Common Stock (2,000 units at $242.25), decreasing direct ownership by 3% to 71,218 units (SEC Form 4)

      4 - RESMED INC (0000943819) (Issuer)

      5/8/25 5:38:05 PM ET
      $RMD
      Medical/Dental Instruments
      Health Care
    • Chief Financial Officer Sandercock Brett sold $215,580 worth of ResMed Common Stock (1,000 units at $215.58), decreasing direct ownership by 1% to 89,864 units (SEC Form 4)

      4 - RESMED INC (0000943819) (Issuer)

      4/10/25 6:14:32 PM ET
      $RMD
      Medical/Dental Instruments
      Health Care
    • Chief Executive Officer Farrell Michael J. exercised 8,009 units of ResMed Common Stock at a strike of $101.64 and sold $1,680,699 worth of ResMed Common Stock (8,009 units at $209.85), decreasing direct ownership by 0.00% to 455,472 units (SEC Form 4)

      4 - RESMED INC (0000943819) (Issuer)

      4/9/25 10:52:15 AM ET
      $RMD
      Medical/Dental Instruments
      Health Care

    $IXHL
    $RMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by ResMed Inc. (Amendment)

      SC 13G/A - RESMED INC (0000943819) (Subject)

      2/10/23 1:36:52 PM ET
      $RMD
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by ResMed Inc. (Amendment)

      SC 13G/A - RESMED INC (0000943819) (Subject)

      2/10/22 5:05:17 PM ET
      $RMD
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by ResMed Inc. (Amendment)

      SC 13G/A - RESMED INC (0000943819) (Subject)

      2/10/22 8:32:59 AM ET
      $RMD
      Medical/Dental Instruments
      Health Care